Edwards Lifesciences Corporation (EW) Stock Analysis 2026

This chart shows how EW's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Edwards Lifesciences Corporation trades at a trailing P/E of 53.70x, generates $1.23B in free cash flow, runs a debt/equity ratio of 6.57, and converts shareholder equity into profit at a 9.2% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Wall Street analysts covering Edwards Lifesciences Corporation currently haven't converged on a clear consensus rating, with a mean 12-month price target of $100.96 (+16.6% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

EW is currently in a short-term downtrend, trading below its 50-day average of $89.46 and above its 200-day average of $84.86. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

In-depth reports on companies operating alongside EW — business models, bull and bear cases, and the metrics that matter.